LOPINAVIR AND RITONAVIR Drug Patent Profile

Which patents cover Lopinavir And Ritonavir, and when can generic versions of Lopinavir And Ritonavir launch?

Lopinavir And Ritonavir is a drug marketed by Lannett Co Inc, Hetero Labs Ltd Iii, Laurus, Macleods Pharms Ltd, Micro Labs, and Mylan Labs Ltd. and is included in six NDAs.

The generic ingredient in LOPINAVIR AND RITONAVIR is lopinavir; ritonavir. There are thirteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the lopinavir; ritonavir profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lopinavir And Ritonavir

A generic version of LOPINAVIR AND RITONAVIR was approved as lopinavir; ritonavir by HETERO LABS LTD III on June 4^th, 2021.

Summary for LOPINAVIR AND RITONAVIR

US Patents:	0
Applicants:	6
NDAs:	6
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	341
Patent Applications:	2,025
DailyMed Link:	LOPINAVIR AND RITONAVIR at DailyMed

Recent Clinical Trials for LOPINAVIR AND RITONAVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
DualityBio Inc.	PHASE1
BioNTech SE	PHASE1
University of Washington	Phase 1

See all LOPINAVIR AND RITONAVIR clinical trials

Pharmacology for LOPINAVIR AND RITONAVIR

Drug Class

Cytochrome P450 3A Inhibitor Protease Inhibitor

Mechanism of Action

Breast Cancer Resistance Protein Inhibitors Cytochrome P450 1A2 Inducers Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inducers Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inhibitors HIV Protease Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors P-Glycoprotein Inhibitors UDP Glucuronosyltransferases Inducers

US Patents and Regulatory Information for LOPINAVIR AND RITONAVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lannett Co Inc	LOPINAVIR AND RITONAVIR	lopinavir; ritonavir	SOLUTION;ORAL	207407-001	Dec 27, 2016		DISCN	No	No
Macleods Pharms Ltd	LOPINAVIR AND RITONAVIR	lopinavir; ritonavir	TABLET;ORAL	204739-002	Jul 25, 2024	AB	RX	No	No
Laurus	LOPINAVIR AND RITONAVIR	lopinavir; ritonavir	TABLET;ORAL	213857-001	Mar 21, 2022	AB	RX	No	No

EU/EMA Drug Approvals for LOPINAVIR AND RITONAVIR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Lopinavir/Ritonavir Mylan	lopinavir, ritonavir	EMEA/H/C/004025Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.	Authorised	yes	no	no	2016-01-14
AbbVie Deutschland GmbH Co. KG	Kaletra	lopinavir, ritonavir	EMEA/H/C/000368Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older.The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.	Authorised	no	no	no	2001-03-19

Market Dynamics and Financial Trajectory for Lopinavir and Ritonavir

Last updated: March 1, 2026

What are the current market drivers for Lopinavir and Ritonavir?

Lopinavir and Ritonavir are antiretroviral drugs primarily used to treat HIV/AIDS. Ritonavir functions as a pharmacokinetic booster for Lopinavir, enhancing its efficacy. Originally developed by Abbott Laboratories, the drugs gained widespread adoption after their approval in the early 2000s. Their market remains active due to persistent HIV prevalence.

Key drivers include:

• Ongoing HIV treatment protocols worldwide, especially in regions with high HIV prevalence like Sub-Saharan Africa, Southeast Asia, and Latin America.
• Consolidation of HIV treatment regimens that include boosted protease inhibitors.
• The emergence of generic versions expanding market access.

In recent years, research exploring additional antiviral uses, including potential applications against other viral infections, has emerged but remains limited.

How has the regulatory landscape impacted market prospects?

Lopinavir and Ritonavir received FDA approval in 2000 for HIV-1 infection. Regulatory pathways for generic manufacturing have accelerated since patent expirations, notably:

• Patent expiry in the U.S. occurred in 2017 for the original formulations.
• Several regulatory agencies, including the EMA and FDA, have approved generic versions, increasing market access.

Regulations favoring affordable HIV therapies and policies for expanding access in low-income countries have amplified the market size.

What is the current competitive landscape?

The market has transitioned towards generics due to patent expirations:

Segment	Market Share (2022)	Key Players
Branded	20%	AbbVie, originator company
Generics	80%	Mylan, Cipla, Sun Pharma, Hetero, Accord Healthcare

Generic manufacturers dominate, causing downward pressure on prices. New entrants face regulatory hurdles but benefit from established demand.

What are the financial forecasts for Lopinavir and Ritonavir?

The global antiretroviral drugs market was valued at approximately US$ 29 billion in 2022 and is projected to grow at a CAGR of 4% through 2030. Key points:

• Demand remains steady in low- and middle-income economies due to ongoing HIV/AIDS burden.
• The shift toward combination therapies and newer drugs like integrase inhibitors reduces reliance on protease inhibitors.
• Price erosion is expected for generic versions, with prices decreasing by an estimated 2-5% annually post-patent expiry.

Manufacturers shifting focus to newer drugs or formulations could impact revenue from Lopinavir and Ritonavir. Companies holding exclusive rights or specialized formulations maintain more stable margins.

What potential market risks exist?

Risks include:

• Competition from newer antiretrovirals with better efficacy and safety profiles.
• Regulatory challenges in maintaining exclusivity.
• Market saturation in high-income countries.
• Supply chain disruptions in manufacturing for generics, especially in countries with complex regulatory environments.

How might emerging antiviral research influence future revenue?

While no immediate replacements are projected, ongoing research into alternative therapies could:

• Reduce demand for existing drugs.
• Lead to off-label use for other viral infections, including COVID-19, where some studies investigated these drugs, but with limited success.
• Increase generic competition in markets with little regulation.

How does pricing policy affect market volume?

Pricing policies in developing countries prioritize affordability, frequently leading to negotiations for lower prices and increased volume. Conversely, in high-income markets, higher prices can sustain revenue streams for originators, albeit with market share constraints.

Key Takeaways

• The market for Lopinavir and Ritonavir remains driven by ongoing HIV treatment needs and widespread generic availability.
• Patent expirations have shifted the landscape toward generics, compressing prices and margins.
• Growth in the overall antiretroviral market is steady but faces pressure from newer drug classes.
• Regulatory and supply chain challenges pose risks but are balanced by high demand in underserved regions.
• Revenue prospects depend heavily on market penetration in low-income regions and competition from newer therapies.

FAQs

1. Will Lopinavir and Ritonavir regain market share in the future?
Limited. The drugs face competition from newer, more tolerable antiretrovirals, and market shifts favor single-tablet regimens with better safety profiles.

2. How do patent expirations affect the global supply of Lopinavir and Ritonavir?
Patent expirations enable generic manufacturing, increasing supply and reducing prices, especially in low-income settings.

3. Are there emerging alternatives that threaten this drug duo?
Yes. Integrase inhibitors like Dolutegravir and newer protease inhibitors with improved pharmacokinetics threaten Lopinavir/Ritonavir’s market position.

4. How significant is the impact of COVID-19 on this market?
Limited impact. While some investigational studies used Lopinavir/Ritonavir for COVID-19, clinical efficacy was not demonstrated, preventing a surge in demand.

5. What strategies could sustain revenue for manufacturers?
Focusing on emerging markets, developing fixed-dose combinations, and maintaining regulatory access are critical. Innovation in formulations and exploring alternative uses also offer potential.

---

References

[1] World Health Organization. (2022). Global HIV/AIDS Statistics. https://www.who.int/hiv/data [2] Grand View Research. (2023). Antiretroviral drugs market size & trends. https://www.grandviewresearch.com [3] U.S. Food and Drug Administration. (2023). Approvals and patent info. https://www.fda.gov [4] IQVIA. (2022). Global Markets for HIV/AIDS Therapeutics. https://www.iqvia.com [5] EMA. (2023). Regulatory environment for HIV medicines. https://www.ema.europa.eu